argenx (NASDAQ: ARGX) is one of 92 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare argenx to similar companies based on the strength of its analyst recommendations, risk, profitability, institutional ownership, dividends, valuation and earnings.
This table compares argenx and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for argenx and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
argenx currently has a consensus target price of $108.50, indicating a potential upside of 13.93%. As a group, “Biological products, except diagnostic” companies have a potential upside of 16.08%. Given argenx’s competitors higher probable upside, analysts plainly believe argenx has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares argenx and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|argenx||$44.74 million||-$31.73 million||-68.00|
|argenx Competitors||$1.03 billion||$94.79 million||-1.79|
argenx’s competitors have higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
52.8% of argenx shares are held by institutional investors. Comparatively, 51.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 17.5% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.